Intravenous administration of vitamin C, often in the form of sodium ascorbate, has attracted great interest from scientists due to its biochemical and physiological properties. Researchers are analyzing its potential significance in conditions associated with oxidative stress, inflammation, disorders of immune system function, and changes in cellular metabolism.
Unlike vitamin C taken orally, intravenous administration delivers ascorbate directly into the bloodstream, bypassing the limitations associated with intestinal absorption. This allows the serum concentration of vitamin C to temporarily reach levels that are usually not achieved through diet or oral supplementation. This difference in exposure has become the basis for research on intravenous vitamin C in many fields of medicine, including oncology, intensive care, cardiology, metabolic disorders, and immunology [1].
However, higher concentrations of the substance in the blood do not automatically mean greater clinical effectiveness. The biological effect of vitamin C depends on its concentration, the cellular environment, metabolic conditions, and the processes being analyzed. Therefore, the results of laboratory experiments, animal studies, and clinical trials must be interpreted separately.
The article discusses the pharmacokinetics, molecular mechanisms, results of experimental and clinical studies, and safety issues associated with intravenous administration of vitamin C. The text presents a scientific review of the topic, without recommending its clinical use or presenting therapeutic regimens.
Pharmacokinetics and bioavailability of vitamin C administered intravenously
The pharmacokinetics of vitamin C differ significantly depending on whether it is administered orally or intravenously. These differences affect the concentrations achieved in the blood and tissues, as well as the duration of exposure in the body.
After oral administration, the absorption of vitamin C is regulated by sodium-dependent vitamin C transporters, primarily SVCT1 and SVCT2, which are involved in its transport and distribution. As the amount consumed increases, the intestinal absorption efficiency decreases, which limits the portion of vitamin C reaching the systemic circulation.
Studies indicate that absorption efficiency decreases when the oral intake exceeds about 200–400 mg per day. As the concentration of vitamin C in the blood increases, the kidneys also participate in maintaining its balance by removing excess from the urine [6, 7].
As a result, increasing the oral supply of vitamin C does not lead to a proportional increase in its concentration in the plasma. With higher doses, the relationship between consumption and the achieved concentration becomes increasingly less linear.
Intravenous administration bypasses the intestinal absorption phase. This allows the introduction of a significantly larger amount of ascorbate directly into the bloodstream in a relatively short time.
In pharmacokinetic studies, serum concentrations of vitamin C were noted to be approximately 30–70 times higher than those typically achieved after oral administration. In studies involving high intravenous exposure, transient concentrations exceeding 10–20 micromoles per liter (mM) were also documented [7].
These concentrations are important because vitamin C can exhibit different biological properties under physiological and pharmacological exposure.
At normal concentrations, its biological activity is primarily associated with antioxidant protection and enzyme-dependent functions. At much higher concentrations, additional chemical reactions, including oxidative processes occurring outside the cells, may take on importance.
However, the ability to achieve a certain concentration in the plasma does not mean that this concentration will yield a clinically significant result.
Pharmacokinetic studies show what happens to a substance after it is administered. Only clinical studies allow us to assess whether a specific exposure profile leads to measurable benefits or harms in specific populations of patients.
Distinguishing between exposure to the substance and the clinical outcome is fundamental to understanding current research on intravenous vitamin C.
Biology of redox processes and molecular mechanisms
Vitamin C plays an important role in regulating the oxidative-reduction processes occurring in cells. Redox processes involve the transfer of electrons between molecules and help maintain the balance between oxidation reactions and antioxidant defense mechanisms.
In physiological concentrations, ascorbate acts primarily as a reducing agent and antioxidant. It participates in reactions that limit oxidative damage and supports the proper functioning of cellular antioxidant systems.
Reactive oxygen species (ROS) are produced during normal cellular metabolism and participate in many signaling pathways. However, their excessive production or insufficient activity of antioxidant mechanisms can lead to oxidative stress and damage to proteins, lipids, and nucleic acids.
Vitamin C helps regulate these processes by donating electrons and participating in biochemical reactions essential for maintaining the functions of cells.
Its activity is not limited to direct antioxidant action. Vitamin C also supports the activity of many enzymatic systems and participates in broader metabolic and physiological processes.
At pharmacological concentrations, the chemical behavior of ascorbate can become more complex.
Under certain experimental conditions, high concentrations of ascorbate outside the cells can participate in oxidation reactions leading to the formation of hydrogen peroxide and other reactive intermediates [6].
This introduces an important distinction between the physiological antioxidant activity and the concentration-dependent prooxidative activity.
Both descriptions do not have to be contradictory. They refer to different chemical environments and exposure conditions.
In experimental studies, the effects of overphysiological levels of ascorbate on the formation of extracellular hydrogen peroxide, the signaling of immune cells, and endothelial responses were analyzed.
In reviews of biochemical studies, these mechanisms were also discussed from the perspective of molecular and systems biology, taking into account the relationships between redox balance, inflammatory signaling, and the function of blood vessels.
These studies help explain why intravenous vitamin C continues to arouse the interest of scientists. However, the results regarding the mechanisms of action should not be taken as evidence that identical effects occur in human tissues at concentrations of clinical significance.
Prooxidative activity and cellular selectivity
One of the most frequently discussed experimental properties of ascorbate at pharmacological concentrations is the ability to induce prooxidative activity under certain biochemical conditions.
When the concentration of ascorbate outside the cells reaches high values, it can participate in reactions leading to the formation of hydrogen peroxide (H₂O₂).
Hydrogen peroxide is one of the reactive forms of oxygen involved in cellular signaling. At elevated concentrations or with impaired antioxidant protection, it can also contribute to oxidative damage.
Laboratory and preclinical studies suggest that some pathological cells, particularly selected cancer cells, may be more susceptible to such oxidative conditions than normal cells [1, 2].
One of the proposed explanations concerns differences in the mechanisms of antioxidant defense. Individual cells differ in their ability to neutralize hydrogen peroxide and control oxidative stress.
For example, enzymes responsible for removing hydrogen peroxide can influence whether hydrogen peroxide is quickly destroyed or accumulates in quantities sufficient to disrupt cellular processes.
In some experimental cancer models, increased susceptibility to oxidative damage was observed during exposure to pharmacological concentrations of ascorbate. However, other cells were able to maintain sufficient protective capacity to tolerate comparable experimental conditions.
However, potential selectivity should not be considered a universal characteristic of cancer cells.
Individual tumors differ in their metabolic properties, antioxidant defense capacity, genetic characteristics, and response to oxidative stress.
Similarly, normal tissues are not automatically protected against all the consequences of increased exposure to ascorbate.
The results of studies in cell cultures and animal models provide the basis for further analysis, but they do not prove the selective destruction of tumors in patients or that intravenous vitamin C improves the survival of people with cancer.
Distinguishing between experimental cell susceptibility and clinical therapeutic efficacy remains crucial.
Modulation of immune function and inflammatory processes
Vitamin C participates in many processes related to the functioning of the immune system, including cell differentiation, immunological signaling, and the regulation of oxidative processes.
Its biological role includes both innate and acquired immunity.
Immune cells of innate origin, such as neutrophils and macrophages, participate in the early response to pathogens and tissue damage. Acquired immune cells, including lymphocytes, are responsible for more specific and long-lasting immune responses.
Scientists studied the role of vitamin C in neutrophil chemotaxis, macrophage phagocytosis, and lymphocyte proliferation [5].
Chemotaxis means the directed movement of immune cells towards chemical signals. Phagocytosis involves the absorption and processing of particles, microorganisms, or cellular debris. Lymphocyte proliferation enables the increase in the number of immune cells during an immune response.
Vitamin C can influence these processes through its involvement in cellular metabolism, redox balance regulation, and signaling pathways.
The researchers also analyzed the relationships between ascorbate exposure and inflammatory mediators, including interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α).
These cytokines participate in communication between immune cells and help coordinate the inflammatory response.
Changes in cytokine concentrations may indicate a modification of immune signaling. However, a decrease in the level of a specific inflammatory marker does not necessarily indicate an improvement in immune system function or a more favorable clinical outcome.
Inflammation is not only a harmful phenomenon; it also plays an important role in the body's defense and tissue repair.
Therefore, the interpretation of the results regarding resistance requires consideration of the type of disease, the time of measurement, the cellular environment, and the endpoints being evaluated.
These issues are particularly important in diseases associated with impaired regulation of the immune response, chronic inflammation, or changes in cytokine signaling.
Although experimental and clinical studies have analyzed intravenous vitamin C under such conditions, the effect on immune biomarkers should not be considered evidence of clinical efficacy.
Intravenous vitamin C in studies of critical conditions and sepsis
Sepsis is a severe clinical condition in which an inappropriately regulated body's response to an infection can lead to life-threatening organ failure.
Its biological mechanisms may include systemic inflammation, oxidative stress, endothelial damage, impaired microcirculation, and abnormalities in cellular metabolism.
These processes prompted scientists to investigate whether vitamin C can affect selected biological pathways associated with critical states.
Vitamin C participates in antioxidant protection and regulates endothelial function, which is why it has become of interest in sepsis research.
In clinical trials, intravenous vitamin C was analyzed both as a standalone intervention and in combination with substances such as thiamine and corticosteroids.
In some randomized and observational studies, changes in surrogate endpoints were observed, including the demand for vasopressin medications, measurements related to endothelial function, and inflammatory biomarkers [11, 14].
Vasopressive medications are used in intensive therapy to maintain arterial pressure and circulation. Reducing the need for these medications may have clinical significance, but it should be interpreted in the broader context of organ function, survival, and other treatment outcomes.
Similarly, changes in endothelial biomarkers or inflammatory parameters can provide information about biological responses, without simultaneously proving an improvement in the patient's condition.
However, the results of the clinical studies were not unequivocally positive.
Larger randomized studies and systematic reviews have yielded inconsistent results, especially with regard to the most important endpoints, such as mortality [1, 15].
An important randomized trial involving adult patients with sepsis, published in 2022 in the „New England Journal of Medicine”, highlighted the risk of assuming that beneficial biological mechanisms must translate into improved treatment outcomes [3].
Differences between studies may result from patient characteristics, disease severity, timing of intervention, exposure levels, concomitant treatment modalities, and selected endpoints.
These factors can make it difficult to compare the results of individual studies.
However, the heterogeneity of the studies should not be used to ignore adverse results or to assume that in other circumstances the benefit would certainly have occurred.
Current evidence does not support intravenous vitamin C as a routine standard of care for sepsis.
Her study remains relevant for intensive care medicine, but the clinical conclusions should primarily be based on properly controlled studies evaluating outcomes that are of direct relevance to patients.
Studies on intravenous vitamin C in oncology
Intravenous vitamin C is studied in oncology because pharmacological levels of ascorbate can produce biochemical effects different from those observed at normal physiological levels.
A significant portion of these studies concerns its potential role as an experimental supportive intervention, rather than a substitute for recognized anti-cancer treatment methods.
Laboratory studies analyzed how elevated ascorbate concentrations affect the metabolism of cancer cells, oxidative stress, and pathways related to the cells' adaptation to limited oxygen availability.
One of the pathways studied is hypoxia-inducible factor 1 alpha (HIF-1α), a regulatory protein involved in the response of cells to conditions of hypoxia.
The researchers also investigated the relationships between exposure to pharmacological concentrations of ascorbate and glycolytic metabolism.
Glycolysis is a metabolic process in which cells obtain energy from glucose. Many cancer cells exhibit altered glucose metabolism, often discussed in the context of the Warburg effect.
Experimental studies suggest that high concentrations of ascorbate can affect selected metabolic and signaling pathways under certain laboratory conditions [1].
However, the metabolic changes observed in cell cultures do not automatically indicate tumor growth control in patients.
In clinical studies in oncology, results such as fatigue, quality of life, inflammatory parameters, and symptoms related to anti-cancer treatment were analyzed.
In some studies, improvements in the results evaluated by patients or selected biomarkers were reported.
These observations may have scientific significance, especially when they relate to symptoms directly experienced by patients.
However, the design of the study, the presence of comparison groups, the number of participants, and the possible influence of the simultaneously used treatment methods remain important.
The reported improvement in fatigue or quality of life does not in itself indicate regression of the tumor or an increase in survival.
Similarly, changes in oxidative stress markers during chemotherapy do not indicate that intravenous vitamin C increases the effectiveness of anti-cancer treatment.
In available controlled clinical trials, no consistent benefit regarding survival has been demonstrated [1, 2].
The overall picture of the research remains therefore ambiguous.
Intravenous vitamin C is still being studied in oncology, but the laboratory mechanisms and preliminary observations reported by patients should not be interpreted as evidence of antitumor efficacy.
Importance for the cardiovascular system and endothelial function
Oxidative stress is involved in many cardiovascular processes, including endothelial dysfunction, myocardial infarction, and non-ischemic reperfusion injuries.
The endothelium is a layer of cells that lines the interior of blood vessels. It participates in the regulation of blood vessel tension, blood flow, inflammatory signaling, and the interactions between blood components and the vessel walls.
One of the important molecules in endothelial physiology is nitric oxide.
Nitric oxide contributes to the relaxation of the smooth muscles of blood vessels and helps regulate their reactivity.
Experimental studies analyzed whether vitamin C can affect the bioavailability of nitric oxide by modifying the oxidative processes involved in its production or decomposition.
Changes in lipid peroxidation and endothelial responses under oxidative stress conditions were also studied [19].
Lipid peroxidation involves the oxidation reactions of lipids, including components of cell membranes.
When oxidative stress exceeds the capabilities of the protective systems, these reactions can contribute to tissue damage.
In some preliminary clinical studies, transient improvements in vascular reactivity or inflammatory parameters have been observed after exposure to intravenous vitamin C in selected populations.
However, a short-term change in vessel function is not equivalent to preventing a heart attack, stroke, or other serious cardiovascular events.
The duration of the observed effect is also important.
The transient physiological response does not indicate a lasting improvement in the health of the blood vessels.
Data from long-term controlled studies evaluating clinical outcomes remain limited, and the significance of many reported vascular changes is uncertain.
Therefore, studies of intravenous vitamin C in cardiology should clearly distinguish between molecular mechanisms, short-term physiological measurements, and the most important clinical results.
Neurological and neurodegenerative studies
Vitamin C participates in many biological processes essential for the functioning of the nervous system.
They include antioxidant protection, cellular metabolism, and biochemical reactions associated with neurotransmitter synthesis.
The nervous system is particularly sensitive to disturbances in energy metabolism and oxidative balance, because the proper functioning of neurons depends on precisely regulated cellular processes.
Oxidative stress and neuroinflammation have been studied in the context of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
These dependencies contributed to the increased interest in molecules involved in neuronal antioxidant protection, including vitamin C [20].
Observational studies have reported associations between higher blood concentrations of vitamin C and selected cognitive health indicators in aging populations.
However, observational studies do not prove a causal relationship.
Individuals with higher levels of vitamin C may differ in their diet, overall nutritional status, health behaviors, co-existing diseases, or other factors affecting cognitive functions.
Therefore, the association between vitamin C levels and cognitive performance does not prove that its intravenous administration improves memory or prevents neurodegeneration.
In preclinical studies, it was also analyzed whether vitamin C can affect the neurons' responses to oxidative damage.
These models provide information about cellular pathways, antioxidant processes, and potential mechanisms of neuroprotection.
However, the results of animal studies and laboratory experiments cannot be automatically applied to neurological diseases in humans.
Evidence regarding specifically intravenous vitamin C in neurodegenerative diseases remains preliminary.
There is insufficient evidence to conclude that intravenous administration prevents Alzheimer's disease, Parkinson's disease, multiple sclerosis, or other neurological disorders.
The importance of vitamin C for neuronal biology is well documented, but its potential clinical role as an intravenous intervention requires separate studies.
Metabolic health and inflammatory diseases
Metabolic disorders such as type 2 diabetes and obesity are often associated with chronic inflammation of low severity, changes in cellular signaling, and increased oxidative stress.
These processes can affect insulin sensitivity, glycemic regulation, the function of blood vessels, and tissue metabolism.
Therefore, vitamin C was studied in the context of metabolic pathways related to insulin signaling, glucose transport, and the expression of inflammatory cytokines [21, 22].
Experimental results suggest that ascorbate may affect selected biochemical processes related to metabolism regulation.
However, a change in the activity of the molecular pathway does not necessarily mean better control of blood glucose levels or a lasting improvement in metabolic health.
Clinical studies analyzed the level of vitamin C and its supplementation in people with metabolic disorders.
In some studies involving intravenous administration, changes in oxidative stress biomarkers or inflammatory markers were noted.
These measurements can help describe biological responses, but their clinical significance remains uncertain without simultaneous improvement in results relevant to patients.
For example, a reduction in levels of oxidative stress markers does not automatically lead to an improvement in insulin sensitivity, sustained glycemic control, or a reduction in the risk of complications of diabetes.
The route of administration also plays a role in the interpretation of the studies.
Studies on oral vitamin C cannot be considered direct evidence regarding intravenous administration, because the serum concentrations achieved and the course of pharmacokinetic processes are different.
One of the cited studies on oral vitamin C in patients with type 2 diabetes reported a partial improvement in vitamin C levels, but without a simultaneous improvement in endothelial dysfunction or insulin resistance [22].
This shows why restoring the correct level of the vitamin or increasing its concentration does not necessarily lead to the expected clinical effect.
Current evidence supports further research into the role of vitamin C in the metabolism of biology, but many questions regarding the lasting clinical results remain unanswered.
Safety issues in scientific research
In some controlled research conditions, intravenous vitamin C has been described as generally well tolerated. However, the results regarding tolerability depend on the population being studied, the exposure conditions, monitoring procedures, and the length of observation.
A positive safety profile in one study does not mean that the intervention is appropriate for every person.
When evaluating the literature on safety, several physiological factors are of particular importance.
Kidney function and metabolism of sulfates
The function of the kidneys is of great importance because the metabolism and elimination of vitamin C involve processes occurring in the renal system.
Vitamin C can participate in the formation of sulfates, and increased exposure to sulfates may be significant in individuals with impaired renal function.
In studies involving patients undergoing hemodialysis, the relationship between intravenous administration of vitamin C and calcium phosphate overload was analyzed [32].
The accumulation of calcium oxalate is of clinical significance because under certain conditions it can contribute to renal complications.
These results show why renal function and sulfate metabolism are important elements in the safety assessment of studies involving high exposure to ascorbate.
However, the results obtained in hemodialysis patients should not be automatically generalized to people with normal kidney function.
Deficiency of glucose-6-phosphate dehydrogenase
The glucose-6-phosphorase dehydrogenase (G6PD) is an enzyme involved in maintaining the oxidative-reductive balance in red blood cells.
Individuals with G6PD deficiency may have limited ability to protect erythrocytes from certain types of oxidative stress.
Therefore, high pharmacological exposure to ascorbate raises concerns regarding the possibility of haemolysis in susceptible individuals.
Hemolysis means the breakdown of red blood cells, which can lead to clinically significant complications.
For this reason, the G6PD status is an important element of the safety assessment in clinical studies involving intravenous administration of high doses of vitamin C [1].
This issue shows that the safety of interventions may depend on individual biological characteristics, and not solely on the substance itself.
Excess iron and its metabolism
Vitamin C participates in the metabolism of iron and may increase the absorption of non-heme iron when taken orally.
This correlation has led researchers to be cautious in considering diseases associated with excessive iron accumulation, such as hemochromatosis [20].
However, the effect of oral vitamin C on intestinal iron absorption should not be equated with the mechanisms occurring during intravenous administration.
The broader topic concerns the interactions between ascorbate, iron availability, and oxidative-reduction reactions.
Iron can participate in redox reactions, and the way it is regulated in the body can influence oxidative processes under certain conditions.
Therefore, disorders related to excessive iron accumulation remain important in the discussion of safety, although the exact significance of these relationships depends on the clinical situation and the route of administration.
Why is medical supervision important?
The presented safety issues show that the biological effect of intravenous vitamin C depends on more than just its concentration in the blood.
Renal function, enzymatic deficiencies, iron metabolism, co-existing diseases, and other physiological characteristics can all influence the individual's response.
Scientific research is also conducted according to specific criteria for the qualification of participants, monitoring procedures, and guidelines for the evaluation of adverse events.
Therefore, observations of good tolerability under controlled conditions should not be taken as evidence in favor of administering the drug without medical supervision.
The absence of reported complications in a small study does not rule out rare adverse effects or risks occurring in other populations.
Reliable safety conclusions require appropriately designed studies, sufficient monitoring, and an appropriately long follow-up period.
More extensive biochemical and pharmacokinetic studies
Beyond clinical studies involving specific diseases, scientists continue to analyze vitamin C under exposure conditions that deviate from normal physiology.
These studies focus on the relationships between ascorbate concentration, redox reactions, cellular signaling, and tissue responses.
One of the important research questions concerns how high extracellular concentrations affect the formation of hydrogen peroxide and the balance between antioxidant and prooxidant processes.
Another topic concerns the function of the endothelium, including the relationships between oxidative stress, nitric oxide signaling, and the reactivity of blood vessels.
Immunological studies also analyzed how the availability of ascorbate affects inflammatory mediators, the activity of immune cells, and cellular responses to physiological stress.
An approach based on systems biology can help analyze these relationships by simultaneously studying multiple molecular pathways, rather than focusing on a single isolated reaction.
However, the results of such studies should remain linked to the experimental models in which they were obtained.
Changes in gene expression, cytokine concentrations, or levels of an oxidative marker do not in themselves indicate a therapeutic effect.
Similarly, a beneficial mechanism observed experimentally does not mean that the corresponding clinical outcome actually occurs.
The value of these studies lies in explaining how vitamin C behaves under different biological conditions, and in identifying questions that could be tested in more rigorous studies.
However, they do not replace evidence from controlled clinical trials.
Summary
Intravenous vitamin C holds a special place in biomedical research because its pharmacokinetics differ significantly from the pharmacokinetics of vitamin C taken orally.
Due to bypassing intestinal absorption, intravenous administration may temporarily lead to plasma concentrations significantly exceeding normal physiological values.
These concentrations have become the basis for research on biochemical processes related to oxidative stress, the formation of hydrogen peroxide, immune signaling, endothelial function, and cellular metabolism.
At physiological concentrations, vitamin C primarily participates in antioxidant protection and essential biochemical reactions. At pharmacological concentrations, it may also exhibit condition-dependent prooxidative activity in certain experimental systems.
This dependence of action on concentration is one of the main reasons why scientists are interested in intravenous vitamin C.
However, pharmacological exposure does not automatically translate into clinical efficacy.
Laboratory studies have identified mechanisms that may be relevant in oncology, critical conditions, metabolic disorders, cardiovascular physiology, and neurological processes.
In some early clinical studies, changes in biomarkers, physiological parameters, or patient-reported outcomes were also observed.
However, the results obtained in these areas remain diverse.
In intensive care and sepsis studies, larger randomized trials did not show consistent improvement in key clinical outcomes. In oncology, laboratory observations and preliminary reports on quality of life did not confirm consistent survival benefits.
Selected short-term biological changes have been observed in cardiovascular and metabolic studies, but evidence of sustained improvement in key health outcomes remains limited.
Neurological studies provide important information about the role of vitamin C in neuronal biology, while the evidence supporting its intravenous administration in neurodegenerative diseases remains preliminary.
Security also requires careful interpretation.
Renal function, sulfate metabolism, G6PD deficiency, iron-related disorders, and individual clinical characteristics can all influence the risk. Therefore, the results obtained in controlled research conditions should not be extrapolated to use without medical supervision.
In general, intravenous vitamin C remains an active subject of pharmacological, biochemical, and clinical research, and not a commonly accepted method of treatment for all the diseases discussed here.
Future studies should clarify which biological mechanisms are of real clinical significance, how individual patient characteristics influence the response, and whether the observed effects translate into a lasting improvement in outcomes that are important to patients.
The most important thing remains the distinction between demonstrating the biochemical effect and confirming a significant clinical benefit.
Disclaimer
This article is for educational and scientific informational purposes only. It presents published studies regarding intravenous vitamin C, including its pharmacokinetics, redox mechanisms, immunological signaling, clinical trial results, and safety issues.
It does not constitute medical advice, does not recommend intravenous administration of vitamin C, does not prescribe treatment regimens, and does not support its use in the treatment of cancer, sepsis, cardiovascular diseases, neurological disorders, metabolic diseases, or other conditions.
The results of laboratory tests, animal experiments, changes in biomarkers, and preliminary clinical observations should not be interpreted as evidence of therapeutic efficacy or safety in humans.
Clinical decisions regarding vitamin C deficiency, supplementation, intravenous preparations, or any medical intervention require evaluation by appropriately qualified healthcare professionals, taking into account available clinical evidence, regulatory information, and the individual patient's situation.
References
- Riordan H. The Riordan Protocol for Intravenous Vitamin C (IVC) in the Adjuvant Treatment of Cancer: IVC as a Chemotherapeutic and Biological Response Modifier. The Orthomolecular Treatment of Chronic Disease, edited by AW Saul, Basic Health Publications, Inc. 2014:750-66.
- Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, et al. Use of intravenous vitamin C in patients with COVID-19: a case series. Expert Rev Anti Infect Ther [Internet]. 2020 Dec 1 [cited 2025 Feb 2];18(12):1259-61.
- Lamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, et al. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit. N Engl J Med [Internet]. 2022 Jun 23 [cited 2025 Feb 2];386(25):2387-98.
- Carpenter K.J. The history of scurvy and vitamin C. Cambridge University Press; 1988Apr 29.
- Jacob RA. Introduction: Three Eras of Vitamin C Discovery. In: Harris JR, editor. Subcellular Biochemistry [Internet]. Boston, MA: Springer US; 1996 [cited 2025 February 2]. pp. 1-16. (Harris JR, editor. Subcellular Biochemistry; vol. 25).
- Hickey S, Roberts HJ, Miller NJ. Pharmacokinetics of oral vitamin C. J Nutr Environ Med [Internet]. 2008 Jan [cited 2025 Feb 2];17(3):169-77.
- Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Ann Intern Med [Internet]. 2004 Apr 6 [cited 2025 Feb 2];140(7):533.
- Paulsen G, Cumming KT, Hamarsland H, Børsheim E, Berntsen S, Raastad T. Can supplementation with vitamin C and E alter physiological adaptations to strength training? BMC Sports Sci Med Rehabil [Internet]. 2014 Dec [cited 2025 Feb 2];6(1):28.
- Evans LW, Zhang F, Omaye ST. Vitamin C supplementation reduces exercise-induced oxidative stress and increases peak muscle strength. Food and Nutrition Sciences. 2017 Aug 2;8(8):812-22.
- Doseděl M, Jirkovský E, Macáková K, Krčmová LK, Javorská L, Pourová J, Mercolini L, Remião F, Nováková L, Mladěnka P, Oemonom. Vitamin C – sources, physiological role, kinetics, deficiency, use, toxicity and determination. Nutrients. 2021 Feb 13;13(2):615.
- Li YR, Zhu H. Vitamin C in sepsis intervention: from redox biochemistry to clinical medicine. Mol Cell Biochem [Internet]. 2021 Dec [cited 2025 Feb 2];476(12):4449-60.
- Pullar JM, Carr AC, Vissers M. The role of vitamin C in skin health. Nutrients. 2017 Aug;9(8):866.
- Naidu KA. Is Vitamin C in Human Health and Disease Still a Mystery? An Overview. Nutr J [Internet]. 2003 Aug 21 [cited 2025 Feb 2];2(1):7.
- Kashiouris MG, L’Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The emerging role of vitamin C in the treatment of sepsis. Nutrients. 2020 Jan 22;12(2):292.
- Xu C, Yi T, Tan S, Xu H, Hu Y, Ma J, Xu J. Association of oral or intravenous vitamin C supplementation with mortality: a systematic review and meta-analysis. Nutrients. 2023 Apr 12;15(8):1848.
- Wilson JX. Mechanism of action of vitamin C in sepsis: Ascorbate modulates redox signaling in endothelium. BioFactors [Internet]. 2009 Jan [cited 2025 Feb 2];35(1):5-13.
- He Z, Li X, Yang H, Wu P, Wang S, Cao D, Guo X, Xu Z, Gao J, Zhang W, Luo X. Effects of oral vitamin C supplementation on liver health and related parameters in patients with nonalcoholic fatty liver disease: a randomized clinical trial. Frontiers in nutrition. 2021 Sep 14;8:745609.
- Traber MG, Buettner GR, Bruno RS. The relationship between vitamin C status, the gut-liver axis, and the metabolic syndrome. Redox biology. 2019 Feb 1;21:101091.
- Morelli MB, Gambardella J, Castellanos V, Trimarco V, Santulli G. Vitamin C and cardiovascular disease: an update. Antioxidants. 2020 Dec 3;9(12):1227.
- Kocot J, Luchowska-Kocot D, Kiełczykowska M, Musik I, Kurzepa J. Does vitamin C influence neurodegenerative diseases and mental disorders? Nutrients. 2017 Jun 27;9(7):659.
- Gonzalez MJ, Miranda-Massari JR, Olalde J. Vitamin C and mitochondrial function in health and exercise. In Molecular Nutrition and Mitochondria 2023 January 1 (pp. 225-242). Academic Press.
- Chen H, Karne RJ, Hall G, Campia U, Panza JA, Cannon RO, et al. High-dose oral vitamin C partially replenishes vitamin C status in patients with type 2 diabetes and low vitamin C status but does not improve endothelial dysfunction or insulin resistance. Am J Physiol-Heart Circ Physiol [Internet]. 2006 Jan [cited 2025 Feb 2];290(1):H137-45.
- Peake JM. Vitamin C: the effects of exercise and training demands. International Journal of Sport Nutrition and Exercise Metabolism. 2003 Jun 1;13(2):125-51
- Lewis N, Hodgson A, Khanbhai T, Sygo J, Mazur J, Smith C, Catterson P, Pedlar C. Rise of intravenous nutrition products among professional team sports athletes: reasons to be concerned? British Journal of Sports Medicine. 2022 Nov 1;56(21):1204-5.
- Burri BJ, Jacob RA. Human metabolism and the requirement for vitamin C. ANTIOXIDANTS IN HEALTH AND DISEASE SERIES. 1997 May 5:341-66.
- Padayatty S, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis [Internet]. 2016 Sep [cited 2025 Feb 2];22(6):463-93.
- Wacker DA, Burton SL, Berger JP, Hegg AJ, Heisdorffer J, Wang Q, Medcraft EJ, Reilkoff RA. Evaluating vitamin C in septic shock: a randomized, controlled trial of vitamin C monotherapy. Critical Care Medicine. 2022 May 1;50(5):e458-67.
- Cameron E. Protocol for the use of vitamin C in the treatment of cancer. Medical Hypotheses. 1 November 1991;36(3):190–4.
- Olczak-Pruc M, Swieczkowski D, Ladny JR, Pruc M, Juarez-Vela R, Rafique Z, Peacock FW, Szarpak L. Vitamin C Supplementation for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Nutrients. 2022; 14: 4217 [Internet]. 2022.
- Xu F, Wen Y, Hu X, Wang T, Chen G. Potential use of vitamin C in preventing kidney damage in patients with COVID-19. Diseases. 2021 Jun 28;9(3):46.
- Honore PM, Spapen HD, Marik P, Boer W, Oudemans-van Straaten H. Dosing vitamin C in critically ill patients with special attention to renal replacement therapy: a narrative review. Annals of intensive care. 2020 Dec;10:1-8.
- Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D, Lanfranco G, Bergamo D, Sandri L, Marangella M. Long-term low-dose intravenous vitamin C administration leads to plasma calcium oxalate supersaturation in hemodialysis patients. American journal of kidney diseases. 2005 Mar 1;45(3):540-9.